Titan Pharmaceuticals, Inc. (TTNP)
NASDAQ: TTNP · Real-Time Price · USD
3.940
+0.410 (11.61%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Company Description
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally.
It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
The company was founded in 1991 and is based in South San Francisco, California.
Titan Pharmaceuticals, Inc.
| Country | United States |
| Founded | 1991 |
| IPO Date | Jan 18, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Weei Chay |
Contact Details
Address: 400 Oyster Point Boulevard, Suite 505 South San Francisco, California 94080 United States | |
| Phone | 650 244 4990 |
| Website | titanpharm.com |
Stock Details
| Ticker Symbol | TTNP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000910267 |
| CUSIP Number | 888314606 |
| ISIN Number | US8883147055 |
| Employer ID | 94-3171940 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jennifer Kiernan | Executive Assistant to Chief Executive Officer and Investor Communications Coordinator |
| Joe Schrei | Executive Director of Commercial Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2025 | 8-K | Current Report |
| Mar 20, 2025 | 10-K | Annual Report |
| Jan 8, 2025 | 8-K | Current Report |
| Jan 3, 2025 | 10-Q | Quarterly Report |
| Dec 6, 2024 | 8-K | Current Report |
| Nov 27, 2024 | 8-K | Current Report |
| Nov 15, 2024 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |
| Nov 8, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 8-K | Current Report |
| Aug 21, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |